genco ship trade limit buy pt time ride rise tide initi coverag buy
rate price analyst jame jang full summari
assumpt coverag
dolphin entertain inc dlpn buy pt assum coverag buy rate price target
appl inc hold pt china iphon miss highlight risk iphon user base declin reduc
estim pt reiter hold rate analyst nehal chokshi full summari
bioscienc inc dare buy pt posit women health pipelin unlock valu
intec pharma ltd ntec buy pt accordion pill program cannibinoid move forward parkinson phase
 buy pt preview execut first step transit loan portfolio reiter buy
rate price analyst michael diana full summari
corpor event call maxim salesperson inform
corpor ctrl cover chokshi ndr chicago cfo mark novakovich wed feb
corpor ctrl cover chokshi ndr boston cfo mark novakovich thu feb
china iphon miss highlight risk iphon user base
declin reduc estim pt reiter
revenu least y/i
magnitud china iphon miss unlik pure attribut weak china
smartphon market lead us assum iphon instal base haircut
risk one year revenu stabil
view cut estim pt multipl result
month pt reduct
revenu least y/i neg pre-announc decemb quarter
result y/i consensu midpoint guidanc
cite lower anticip iphon revenu primarili greater china account
revenu shortfal guidanc given revenu outsid iphon grew
y/i impli iphon revenu y/i manag also note
revenu shortfal guidanc y/i world-wide
revenu declin occur greater china across iphon ipad
estim revenu china declin y/i rang result
assum revenu non-great china region flat-to-up y/i consist
origin midpoint revenu growth guidanc note iphon repres
revenu bulk shortfal iphon estim iphon
revenu china y/i unit like similar
amount flat y/i
magnitud china iphon miss unlik pure attribut weak china
smartphon market lead us assum iphon instal base haircut
forthcom believ modest slowdown china growth see
figur page fulli explain triangul massiv chang
revenu growth trajectori greater china y/i
somewher y/i manag cite market data
shown contract greater china smartphon market particularli
sharp actual data sourc cite also note track monthli
subscrib net add china mobil china unicom china telecom show
signific deterior rate y/i declin month octob
novemb rel earlier year see figur page manag
also note result china includ new record servic revenu instal
base devic grew last year note q/q growth iphon instal
base growth exclud statement believ far import
metric investor especi believ iphon instal base growth
relev metric manag disclos expect averag user
increas number devic time watch ipad
headphon etc servic especi higher asp servic
nativ offer rather low asp servic take
cut avail across given user multipl devic
iphon anchor tie user ecosystem given data
point fear weak china iphon result symptomat china iphon user
move away ecosystem china iphon instal base
contract whether contract due price simpli high potenti
fixabl definit within aapl control rise nation outsid aapl
control favor chines devic maker yet determin clearli risk
materi haircut aapl iphon activ instal base loom larg per analysi
risk one year revenu stabil cut
estim pt multipl result pt reduct
provid rise nation play weak
result china concern instal base greater china iphon
user take multi-year process resiz similar took multi-year process
consum pc instal base resiz result transfer workload
pc tablet mainli ipad assum iphon unit
declin y/i remaind y/i
also assum instal base contract per year next
three year non- nativ subscript servic pay music
icloud forthcom news video declin per year next three
year well result project revenu declin end
revenu stabil result project ep bottom
move price target basi
addit given materi risk face iphon instal
base declin multipl year also reduc price target multipl
in-lin hdd multipl use seagat stx
hold buy compar
given chang pt mechan estim reduc
month price target
click full note
time ride rise tide initi coverag buy
rate price target
initi coverag genco ship owner one
largest diversifi fleet dri bulk vessel
dri bulk sector climb toward mid-cycl rate look ep
expans regul allow
global fleet slow-steam essenti shrink fleet
method approach enabl realiz higher fuel
save earn market-r capes fleet ahead peer
success refinanc facil push matur
afford capit fleet renewal/expans
initi coverag buy rate price target price target
base multipl forward normal
initi coverag genco owner one largest well-diversifi
dri bulk fleet own one largest highli diversifi fleet within
publicli trade ship space genco fleet vessel compris capes
five panamax supramax six ultramax handys vessel believ
larg diversifi fleet could enabl compani realiz outsiz earn dri
bulk sector climb toward sustain recoveri project capes
rate averag per vessel/day per vessel/day
see figur level per vessel/day see figur
flexibl charter strategi key genco current employ vessel short-
term charter spot market manag expect dri bulk rate increas
move closer start januari flexibl charter
strategi help minim downsid risk allow upsid market
method approach scrubber set instal capes
first intern maritim organ imo mandat januari
ocean go vessel limit sulfur emiss taken
step outfit capes vessel fleet scrubber
compani hold option instal scrubber fleet minor bulk
vessel initi step instal scrubber larger capes vessel provid
natur hedg widen fuel spread capes account
compani total fuel consumpt
credit facil refinanc balloon payment push
genco success refinanc four credit facil two facil push
matur prior refinanc requir make quarterli
instal balloon million due million due
million due addit lower spread libor bp
libor bp healthi balanc sheet place believ compani
could look acquir addit tonnag industri consolid
valuat attract current level current trade
estim believ discount warrant expect
compani outperform dri bulk peer due forward-think manag
structur larg diversifi fleet healthi balanc sheet sinc manag
made prudent strateg decis allow genco outperform
therefor initi coverag buy rate price target
price target base multipl forward normal
click full note
preview execut first step transit loan
portfolio reiter buy rate price target
report ep octob manag laid plan
acceler transit loan portfolio commerci loan
fewer residenti mortgag loan sell least long-
term fixed-r single-famili mortgag use proce acquir
portfolio commerci financ loan buy back stock
announc decemb agre sell
long-term single-famili mortgag schedul close februari
repurchas million share common stock equal
outstand share would use proce mortgag sale
pay wholesal borrow
manag expect sale/reduct borrow neutral
earn increas core net interest margin exclud accret incom
loan result accret incom loan
reduc
confer call manag also indic expect
acquir portfolio commerci financ loan subject
reason acquisit price judg lack mention portfolio
acquisit recent press releas assum still pursu
option
maintain ep estim like report
januari ep estim page
earn model share current trade ep estim
maintain price target equat
ep estim consist best-in-class mid-cap bank
stl flexibl view estim price target might
view aggress regard reason emphas
remain best idea
investor miss two major point view power total
earn asset single-famili multi-famili mortgag acquir astoria roll
sold replac commerci loan yield
higher therebi offset deposit price pressur redund
ineffici acquir expens base astoria enabl
oper expens flat-to-down three year even includ materi new
expens grow commerci busi detail discuss
point see note pound tabl high upsid downsid
reiter buy rate next four quarter expect stock price
appreci price target dividend yield
result estim total return
click full note
assum coverag buy rate price
favor view dolphin posit public relat space
opportun grow new vertic
growth televis movi content foster demand public
relat servic compani offer
expect movi product distribut provid second leg
growth start
compel valuat stock trade ep estim
price target base ep also
support dcf analysi
dolphin entertain offer attract growth entertain market
product favor view compani posit public
relat opportun expand new vertic near-
term expect entertain pr main contributor revenu ebitda
larg market new content creation tradit new media compani
provid attract backdrop relat market spend dolphin own
highli regard west larg opportun consolid
highli fragment industri compani recent acquisit viewpoint creativ
alreadi increas presenc pr space featur cw
compani also attract opportun content product distribut
focus famili entertain compani target first film
posit view lower-risk product strategi limit up-front
invest benefit strong promot pr busi expect
revenu grow driven integr recent
acquisit first film releas look roughli flat ep due higher
share count doubl
compel valuat stock current trade ep estim
price target base ep compani
expect ramp content product busi current slate film
view first full year resembl cash flow divis valuat
also support dcf-base analysi dcf util multipl
termin period calcul weight averag cost capit wacc
compani profil dolphin entertain dlpn lead entertain
market premium content develop compani two report segment
entertain public content product entertain public divis
highlight entertain pr firm acquir march provid
strateg market public servic major film studio mani digit
content provid addit hundr a-list celebr includ actor artist
produc director athlet author addit entertain public
divis includ lead lifestyl hospit public relat creativ
brand market servic agenc acquir juli viewpoint
creativ full servic creativ brand product agenc acquir novemb
click full note
accordion pill program cannibinoid move forward
intec announc studi accordion pill ap evalu ap-thc
tetrahydrocannabinol dose first subject studi enrol
healthi subject evalu safeti pharmacokinet pk pk
studi ap-cbd cannabidiol plan intec expand ap
prior studi plant-bas cbd formul ap
bioavail significantli improv compar sublingu spray
sativex intec pursu medic cannabinoid pain indic
parkinson diseas ap-cpld phase updat trial enrol
pd patient reach random target outlin
addit detail expect data addit pk
studi ap-cd/ld dose daili complet enrol
accordion pill ap deliveri medic cbd prior phase studi ap
formul plant-deriv tetrahydrocannabinol cbd cannabidiol
ratio ap-cbd/thc evalu safeti pk two differ dose vs sativex gw
pharmaceut gwph nr sativex sublingu spray cannabi extract
deliv cbd use allevi neuropath pain spastic
symptom multipl sclerosi overact bladder phase studi ap-thc/
cbd conduct healthi subject ac formul demonstr signific
improv bioavail cbd
compar sativex median time reach peak concentr
longer ap formul also result reduct metabolit
intec plan pursu develop medic cannabinoid use pain indic
today new phase studi ap-thc dose first healthi subject studi
enrol subject evalu safeti pk expect follow
ap-cbd studi
updat phase program parkinson diseas pd random multi-
center site double-blind phase accord studi evalu
accordion pill carbidopa/levodopa ap-cd/ld treatment parkinson diseas
symptom advanc pd patient trial complet enrol
target random intec updat progress trial
note trial random averag age patient
male averag diagnosi pd year averag daili dose
levodopa upon enter blind portion studi common ap
dose per day averag daili off-tim enter random portion
studi hr patient us pend complet
random week endpoint top-lin data expect
commerci side commerci scale machin produc ap-cd/ld pass
factori test instal partner lt lohmann therapie-system
ag privat valid bridg stabil studi plan
requir regulatori approv nda submiss plan mid-lat
click full note
posit women health pipelin unlock valu
manag provid updat anticip catalyst timelin
women pipelin program focu two late-stag
program phase ovapren recent acquir phase asset
bacteri vaginosi
addit on-going program list upon secur fund
compani also plan develop inject etonogestrel
contracept catsper non-hormon contracept use
men women
conclus view manag construct uniqu pipelin
divers product candid women health space posit result
upcom mileston ovapren topic sildenafil could
repres import valuat driver dare share view
upcom catalyst
complet content valid studi topic sildenafil sildenafil cream
femal sexual arous disord fsad
initi phase studi at-hom topic sildenafil fsad
top-line data phase intravagin ring
final formul vaginally-deliv tamoxifen
vulvar vagin atrophi vva women hormon receptor posit breast
initi phase trial formerli antibiot
clindamycin bacteri vaginosi bv
top-line data phase post-coit test pct clinic trial ovapren
hormone-fre contracept ring
ovapren hormone-fre monthli vagin contracept ring creat
spermiostat environ silicon matrix releas ascorb acid ferrou
glucon effect cut tail sperm non-braid multi-fila
mesh barrier design block sperm attempt enter cervic canal
two compon could produc similar efficaci diaphragm short-act
hormon option vagin ring pill patch ovapren may meet women
prefer characterist long-act hormone-fre birth control current
avail method ovapren devic pma pathway phase mid-stag
post-coit clinic trial pct on-going data
formerli incorpor proprietari in-situ gel system
formul clindamycin form bioadhes gel extend releas
drug clindamycin antibiot use treat bacteri infect bv
drug dual releas pattern vagin applic provid
maximum durat exposur clindamycin site infect pilot
studi demonstr cure rate bv one dose
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
